KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Current Assets (2019 - 2025)

Royalty Pharma's Current Assets history spans 7 years, with the latest figure at $1.5 billion for Q4 2025.

  • For Q4 2025, Current Assets fell 15.21% year-over-year to $1.5 billion; the TTM value through Dec 2025 reached $1.5 billion, down 15.21%, while the annual FY2025 figure was $1.5 billion, 15.21% down from the prior year.
  • Current Assets for Q4 2025 was $1.5 billion at Royalty Pharma, down from $1.8 billion in the prior quarter.
  • Across five years, Current Assets topped out at $3.5 billion in Q2 2022 and bottomed at $1.3 billion in Q4 2023.
  • The 5-year median for Current Assets is $2.4 billion (2021), against an average of $2.3 billion.
  • The largest annual shift saw Current Assets tumbled 50.13% in 2023 before it soared 41.43% in 2024.
  • A 5-year view of Current Assets shows it stood at $2.9 billion in 2021, then dropped by 11.23% to $2.6 billion in 2022, then tumbled by 50.13% to $1.3 billion in 2023, then surged by 41.43% to $1.8 billion in 2024, then dropped by 15.21% to $1.5 billion in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Current Assets are $1.5 billion (Q4 2025), $1.8 billion (Q3 2025), and $1.5 billion (Q2 2025).